Entrada Therapeutics Analyst Ratings
BenzingaMar 18 06:36 ET
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
TipRanksMar 13 10:25 ET
Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22
BenzingaJan 5 07:23 ET
Entrada Therapeutics Analyst Ratings
BenzingaJan 5 07:22 ET
HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20
BenzingaNov 27, 2023 07:26 ET
Entrada Therapeutics Analyst Ratings
BenzingaNov 27, 2023 07:24 ET
Positive Prospects for Entrada Therapeutics Despite FDA Hold: An Analyst's Buy Rating Justification
TipRanksNov 22, 2023 17:25 ET
Entrada Therapeutics' Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
TipRanksNov 8, 2023 06:32 ET
TD Cowen Remains a Buy on Entrada Therapeutics Inc (TRDA)
TipRanksNov 7, 2023 12:55 ET
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
BenzingaSep 22, 2023 06:31 ET
Entrada Therapeutics Analyst Ratings
BenzingaSep 22, 2023 06:30 ET
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)
TipRanksSep 22, 2023 06:21 ET
Entrada Therapeutics Analyst Ratings
BenzingaAug 9, 2023 06:39 ET
H.C. Wainwright Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
TipRanksAug 9, 2023 06:35 ET
Entrada Therapeutics Inc (TRDA) Gets a Hold From Goldman Sachs
TipRanksAug 2, 2023 17:05 ET
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)
TipRanksAug 2, 2023 06:20 ET
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
BenzingaAug 2, 2023 06:20 ET
Entrada Therapeutics Analyst Ratings
BenzingaAug 2, 2023 06:19 ET
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
BenzingaMay 24, 2023 07:15 ET
Entrada Therapeutics Inc (TRDA) Receives a Buy From H.C. Wainwright
TipRanksMay 24, 2023 06:25 ET
No Data
No Data